Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
01/12/2025 13:33
Dec 1 (Reuters) - NanoViricides, Inc NNVC.A: NANOVIRICIDES: SIGNED MASTER SERVICES AGREEMENT WITH ONLY ORPHANS COTE FOR ORPHAN DRUG STRATEGY OF NV-387 FOR TREATMENT OF MPOX, SMALLPOX, & MEASLES Source text: [ID:] Further company coverage: NNVC.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NanoViricides,
See all newsExplainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments